STOCK TITAN

RenovoRx appoints Richard Stark as independent director

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

RenovoRx, Inc. (RNXT) appointed Richard Stark as an independent director effective November 18, 2026, expanding its board from six directors to seven. Stark, chief executive officer of Innoblative Designs, Inc., had advised RenovoRx since December 2024.

His consulting agreement ended effective November 15, 2026, and 12,000 unvested options were forfeited. Under the outside-director policy, he received 128,824 options with a $120,000 aggregate grant-date fair value, an exercise price of $1.12 per share and a 10-year term. The options vest 1/36 monthly, subject to continued service, and vest in full upon a change in control, also subject to continued service. His package includes a $40,000 annual cash retainer and an automatically granted option award on October 1, 2027, with $70,000 aggregate grant-date fair value, prorated based on days elapsed since November 18, 2026.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Board size after appointment 7 directors The board increased from six directors effective November 18, 2026.
Unvested options forfeited 12,000 options Forfeited under the consulting termination agreement effective November 15, 2026.
Initial director option award 128,824 options Awarded November 18, 2026.
Initial award grant-date fair value $120,000 Aggregate grant-date fair value.
Option exercise price $1.12 per share Initial award; equal to the common stock closing price on the grant date.
Option term 10 years Initial director award.
Annual cash retainer $40,000 per year Payable quarterly in arrears and prorated for a partial quarter of service.
Future option award grant-date fair value $70,000 aggregate Award to be granted October 1, 2027, prorated based on days elapsed from November 18, 2026.
grant date fair value financial
"having a grant date fair value of $120,000 in the aggregate"
The grant date fair value is the estimated dollar worth of a stock-based award (such as stock options or restricted shares) at the exact moment it is given to an employee or contractor. Investors care because companies use that value to record compensation expenses and to show how much potential ownership and earnings dilution those awards could create—think of it as the price tag placed on a gift card when it is handed over so the company can report the cost now.
change in control financial
"will vest in full upon a change in control of the Company"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
TAMP™ (Trans-Arterial Micro-Perfusion) technical
"RenovoRx’s TAMP™ (Trans-Arterial Micro-Perfusion) platform"
Orphan Drug Designation (ODD) regulatory
"received Orphan Drug Designation (ODD) for pancreatic cancer"
Orphan drug designation (ODD) is a regulatory status granted to a medicine intended to treat a rare disease or condition, giving the developer special incentives such as reduced fees, development support, and a period of exclusive market rights. For investors, ODD signals that a product may face less competition, enjoy stronger pricing power, and benefit from lower development costs and regulatory help—similar to receiving a temporary protected license to serve a small but underserved market.
Phase III TIGeR-PaC clinical trial medical
"completed enrollment in the Phase III TIGeR-PaC clinical trial"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who did RenovoRx appoint to its board?

RenovoRx appointed Richard Stark as an independent director effective November 18, 2026, increasing the board from six directors to seven. Stark is chief executive officer of Innoblative Designs, Inc.

What compensation did Richard Stark receive as a RenovoRx director?

He received 128,824 options with a $120,000 aggregate grant-date fair value at an exercise price of $1.12 per share. The options have a 10-year term and vest 1/36 monthly, subject to continued service; they vest in full upon a change in control, also subject to continued service. His policy compensation includes a $40,000 annual cash retainer.

What happened to Richard Stark’s RenovoRx consulting agreement?

The agreement terminated effective November 15, 2026. Under the termination agreement, Stark forfeited 12,000 unvested options. During the consulting arrangement, he received options as compensation and no cash compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001574094 0001574094 2026-11-20 2026-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 20, 2026 (November 18, 2026)

 

RENOVORX, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40738   27-1448452

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2570 W El Camino Real, Suite 640

Mountain View, CA

  94040
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (650) 284-4433

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   RNXT   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Richard Stark as a Director

 

Effective as of November 18, 2026, the Board of Directors (the “Board”) of RenovoRx, Inc., a Delaware corporation (the “Company”), approved an increase the size of the Board from six directors to seven directors and appointed Richard Stark to fill the vacancy on the Board occasioned by such increase (the “Appointment”).

 

The following is certain biographical information regarding Mr. Stark:

 

Richard Stark, age 62, has more than 30 years of leadership experience in the medical technology industry. Since January 2024, he has served as Founder and Managing Member of MedTech Angels, an investment group focused on early-stage medical technology companies. Since January 2021, he has served as Chief Executive Officer of Innoblative Designs, Inc., a medical technology company developing advanced radiofrequency ablation technologies. Since January 2017, he has served as Founder and Principal of RAS Consulting Firm, LLC, advising healthcare companies, boards of directors and investors on commercialization strategy, business development, fundraising, strategic partnerships, mergers and acquisitions, and corporate growth initiatives. Previously, Mr. Stark served as Chief Executive Officer, President, and a member of the board of directors of Sanarus Technologies, a medical device company, from January 2018 to January 2021, where he led the company through the strategic transfer of its technology assets to Hologic, Inc. Prior to Sanarus, he served at AngioDynamics (Nasdaq: ANGO), a medical technology company, as Senior Vice President and General Manager, Global Oncology/Surgery, from January 2010 to January 2018 and as General Manager and Vice President, Sales & Marketing, Oncology/Surgery from January 2007 to January 2010. Earlier in his career, he held senior commercial leadership positions at RITA Medical Systems from January 1999 to January 2007 and leadership roles at Woodside Biomedical and Arrow International from January 1994 to January 1999. Mr. Stark currently serves on the boards of two medical device companies, Pleural Dynamics and Polyembo. Mr. Stark is qualified to serve as a director due to his extensive executive leadership experience, significant board and governance experience, deep knowledge of the medical technology sector, and demonstrated track record of driving growth, innovation, and strategic transactions across healthcare organizations.

 

The Board has determined that Mr. Stark qualifies as an independent director in accordance with the requirements of the Nasdaq Stock Market LLC. Mr. Stark has no family relationships with any of the Company’s directors or executive officers, and he is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Mr. Stark and any other persons pursuant to which he was selected as a director.

 

Prior to the Appointment, Mr. Stark had served as a consultant to the Company since December 5, 2024. In connection therewith, Mr. Stark provided strategic commercial advisory services to the Company as its Strategic Commercial Advisor pursuant to a Consulting Agreement, dated as of December 5, 2024, by and between the Company and Mr. Stark (as amended, the “Consulting Agreement”), as compensation for which Mr. Stark received solely options to purchase shares of the Company’s common stock (the “Common Stock”) granted under the Company’s Amended and Restated 2021 Omnibus Equity Incentive Plan (collectively, the “Consulting Options”) and no cash compensation. On November 11, 2026, the Company and Mr. Stark entered into a Consulting Termination Agreement pursuant to which the Consulting Agreement terminated effective as of November 15, 2026, and pursuant to which unvested Consulting Options to purchase 12,000 shares of Common Stock were forfeited by Mr. Stark.

 

Upon the Appointment, pursuant to Outside Director Compensation Policy of the Company (as amended, the “Policy”), on November 18, 2026, Mr. Stark was awarded 128,824 options to purchase shares of Common Stock having a grant date fair value of $120,000 in the aggregate (the “Initial Award”), with 1/36th of the Initial Award vesting each month on the same day of the month as the commencement of his service as an outside director, subject to his continued service through each vesting date. The Initial Award has a per share exercise price equal $1.12, the closing price of the Common Stock on the grant date, a term of ten years, and will vest in full upon a change in control of the Company, subject to his continued service through such date. In addition, pursuant to the Policy, Mr. Stark will (i) receive an annual cash retainer of $40,000, payable quarterly in arrears and prorated for any partial quarter of service, (ii) be eligible to receive the additional annual cash fees provided under the Policy for service as a chair or member of any committee of the Board to which he may be appointed, and (iii) on October 1, 2027, be automatically granted options to purchase shares of Common Stock having a grant date fair value of $70,000 in the aggregate, prorated based on the number of days elapsed from November 18, 2026 until October 1, 2027, with 1/12th of such award vesting monthly on the first day of each month thereafter, subject to his continued service. Thereafter, Mr. Stark will be eligible to receive the same compensation payable under the Policy to the Company’s other non-employee directors. Mr. Stark will also be reimbursed for his reasonable, customary and documented travel expenses to attend meetings of the Board and its committees.

 

On November 19, 2026, the Company issued a press release announcing the Appointment, a copy of which is filed as Exhibit 99.1 to this Form 8-K and is incorporated by reference herein.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated November 19, 2026, regarding the appointment of Richard Stark to the Board.
104   Cover Page Interactive Data File (embedded within the Inline XBRL Document).

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  RENOVORX, INC.
Date: November 20, 2026    
     
  By: /s/ Shaun R. Bagai
  Name: Shaun R. Bagai
  Title: Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

 

RenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors

 

MOUNTAIN VIEW, Calif. – November 19, 2026 – RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, and evaluating a novel targeted oncology drug-device product candidate, today announced the appointment of Richard A. Stark, Chief Executive Officer of Innoblative Designs, Inc., to the Company’s Board of Directors.

 

Mr. Stark brings more than three decades of leadership experience in medical technology to the RenovoRx Board, with a focus on setting and executing commercialization strategies of interventional oncology medical technologies. He has advised RenovoRx since late 2024, helping its commercial team lay the foundation for the Company’s commercial efforts. He now brings his expertise and knowledge of the RenovoRx’s TAMP™ (Trans-Arterial Micro-Perfusion) platform, enabled by RenovoCath, to the Company’s Board as RenovoRx continues to gain traction in the market and physician adoption across U.S. cancer centers.

 

“We are pleased to welcome Rick to our Board of Directors,” said Shaun Bagai, Chief Executive Officer of RenovoRx. “Beyond his decades of experience in medtech sales and marketing, Rick has been instrumental in building the infrastructure that is accelerating physician adoption of RenovoCath in interventional oncology, and his insight sharpened our commercial approach at a critical juncture. As our market penetration across cancer centers deepens, his boardroom perspective will be important in continuing to shape our commercial strategy and guiding how we scale.”

 

Mr. Stark currently serves as Chief Executive Officer of Innoblative Designs, Inc., a medical technology company developing an RFA electrosurgical platform for intraoperative soft-tissue coagulation and ablation, including development programs in breast-conserving surgery. He is also Founder and Principal of RAS Consulting Firm, LLC, which advises medical technology companies on commercialization strategy, and Founder and Managing Member of MedTech Angels, a physician and executive-led angel investment group focused on medical technology. He serves as an independent director of Pleural Dynamics and Polyembo.

 

“I have spent my career working with oncologists and other physicians to adopt technologies that deliver therapy with greater precision, and I believe RenovoRx is well positioned with RenovoCath at the intersection of innovation and patient impact,” said Mr. Stark. “Having worked as an advisor to the commercial team for nearly two years, I have seen the TAMP platform’s strength firsthand, and I am excited to continue to contribute my experience as a Board member as the Company builds on its innovative approach to targeted therapeutic delivery for patients with difficult-to-treat solid tumors.”

 

 
 

 

About RenovoCath

 

Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-H-Universal-IFU.pdf.

 

About RenovoRx, Inc.

 

RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company commercializing RenovoCath®, a novel, FDA-cleared device for local drug delivery designed to address significant unmet medical needs, with a focus on difficult-to-treat tumors. The Company is also evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath using RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) platform as a novel drug-device product candidate for locally advanced pancreatic cancer.

 

RenovoRx’s patented TAMP™ platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, potentially improving safety, tolerance, and efficacy while minimizing the toxicities associated with systemic intravenous therapy. The Company’s mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

 

RenovoRx completed enrollment in the Phase III TIGeR-PaC clinical trial in August 2026, and anticipates the initial topline data in the second half of 2027. The trial is evaluating its novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered via RenovoCath (IAG). RenovoCath enables IAG, and is FDA-cleared for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. IAG is currently under investigation and has not been approved for commercial sale.

 

RenovoCath with gemcitabine received Orphan Drug Designation (ODD) for pancreatic cancer and bile duct cancer, and oxaliplatin has received ODD for pancreatic cancer, each of which provides seven years of market exclusivity upon new drug application approval by the FDA.

 

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

 

 
 

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release and statements of the Company’s management and third parties made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the anticipated benefits to the Company of the appointment of Mr. Stark to the Company’s Board of Directors as described herein as well as (i) our clinical trials and studies (including expectations for trial completion and data read out), (ii) the potential for our product candidates and our TAMP technology (enabled by RenovoCath) to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, (iii) our efforts to commercialize our RenovoCath and TAMP technology for use in treating pancreatic and other solid tumor cancers, and (iv) our expected financial results from such efforts, including our estimates for 2026 annual revenue and anticipated active commercial sites, as well as statements regarding our cash runway. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our commercial and other business plans, objectives and strategies, our research and development plans, intellectual property development, clinical trials, our therapy platform, financing plans, and expected operating results, all of which are based on current expectations and assumptions that are subject to significant known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “aim,” “goal,” “estimates,” “future,” “intends,” and “potential,” or derivatives of these terms or other comparable terminology regarding RenovoRx’s statements about the future, although not all forward-looking statements contain these words. All forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our commercial efforts for our TAMP technology (enabled by RenovoCath) may not lead to the achievement of our revenue forecasts or to viable, revenue generating operations in general or to the achievement of the number of active cancer center customers we expect; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress, completion and potential results (including the results of interim analyses and final trial data) of our preclinical studies, clinical trials, and our research programs (notably with respect to our Phase III TIGeR-PaC trial); (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that applicable regulatory authorities may disagree with our interpretation of the data, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our TAMP therapy platform for drug-delivery to treat other forms of cancer or to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of RenovoCath as a standalone device or our product candidates, if such product candidates are approved by the FDA; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, needs for additional financing, our ability to obtain additional capital and our ability to maintain the listing of our common stock on Nasdaq; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified personnel; (xvii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xviii) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xix) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xx) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission, which can be accessed at https://ir.renovorx.com/sec-filings.

 

As a result of the foregoing, you are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

 

Investor Contact:

 

ICR Healthcare

 

Stephanie Carrington or Adanna G. Alexander, Ph.D.

 

T: 646-277-1282

 

Renovorx@icrhealthcare.com

 

Media Contact:

 

STiR Communications

 

Hannah Williams

 

T: 803-521-1214

 

hannah@stir-communications.com

 

 

Filing Exhibits & Attachments

5 documents

Keep reading